Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $43.00 USD
Change Today +3.63 / 9.22%
Volume 2.2M
XON On Other Exchanges
Symbol
Exchange
New York
Frankfurt
As of 8:04 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

intrexon corp (XON) Snapshot

Open
$39.60
Previous Close
$39.37
Day High
$43.06
Day Low
$39.60
52 Week High
03/4/15 - $50.98
52 Week Low
05/9/14 - $13.13
Market Cap
4.5B
Average Volume 10 Days
1.4M
EPS TTM
$-1.08
Shares Outstanding
105.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for INTREXON CORP (XON)

intrexon corp (XON) Related Businessweek News

View More BusinessWeek News

intrexon corp (XON) Details

Intrexon Corporation, a biotechnology company, operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. Its technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; cell systems informatics; RheoSwitch inducible gene switch; AttSite Recombinases; protein engineering; mAbLogix; and laser-enabled analysis and processing. Intrexon Corporation has collaboration agreements with ZIOPHARM Oncology, Inc.; Synthetic Biologics, Inc.; Oragenics, Inc.; Fibrocell Science, Inc.; Genopaver, LLC; AquaBounty Technologies, Inc.; S & I Ophthalmic, LLC; Biological & Popular Culture, Inc.; OvaXon, LLC; Intrexon Energy Partners, LLC; and Persea Bio, LLC. The company was formerly known as Genomatix Ltd. and changed its name to Intrexon Corporation in 2005. Intrexon Corporation was founded in 1998 and is based in Germantown, Maryland.

480 Employees
Last Reported Date: 03/2/15
Founded in 1998

intrexon corp (XON) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: --
Chief Operating Officer
Total Annual Compensation: $2.1M
Senior Vice President of Energy Sector and Pr...
Total Annual Compensation: $341.0K
Compensation as of Fiscal Year 2013.

intrexon corp (XON) Key Developments

Intrexon Corporation Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014

Intrexon Corporation reported unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported total revenues of $31,092,000 compared to $7,143,000 a year ago. Operating loss was $18,961,000 compared to $17,726,000 a year ago. Income before tax was $17,806,000 compared to loss before tax of $13,018,000 a year ago. Net income attributable to the company was $18,831,000 or $0.18 per diluted share compared to net loss attributable to the company of $12,204,000 or $0.13 per diluted share a year ago. Adjusted LBITDA was $5,535,000 compared to $7,162,000 a year ago. Pro forma adjusted LBITDA per basic and diluted share was $0.06 compared to $0.07 a year ago. For the year, the company reported total revenues of $71,930,000 compared to $23,760,000 a year ago. Operating loss was $69,962,000 compared to $58,023,000 a year ago. Loss before tax was $85,719,000 compared to $40,908,000 a year ago. Net loss attributable to the company was $81,822,000 or $0.83 per diluted share compared to $38,980,000 or $1.40 per diluted share a year ago. Adjusted EBITDA was $3,219,000 compared to adjusted LBITDA of $23,738,000 a year ago. Pro forma adjusted EBITDA per basic and diluted share was $0.03 compared to loss per share of $0.27 a year ago.

Intrexon Corporation to Report Q4, 2014 Results on Mar 02, 2015

Intrexon Corporation announced that they will report Q4, 2014 results at 5:00 PM, Eastern Standard Time on Mar 02, 2015

Intrexon Corporation, Q4 2014 Earnings Call, Mar 02, 2015

Intrexon Corporation, Q4 2014 Earnings Call, Mar 02, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
XON:US $43.00 USD +3.63

XON Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alexion Pharmaceuticals Inc $180.59 USD +4.55
MorphoSys AG €57.00 EUR -0.94
XOMA Corp $3.64 USD +0.05
View Industry Companies
 

Industry Analysis

XON

Industry Average

Valuation XON Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 60.1x
Price/Book 11.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 60.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INTREXON CORP, please visit www.dna.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.